Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.
Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Elias AD, et al. Among authors: sams s. NPJ Breast Cancer. 2023 May 20;9(1):41. doi: 10.1038/s41523-023-00544-z. NPJ Breast Cancer. 2023. PMID: 37210417 Free PMC article.
Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.
Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Brechbuhl HM, et al. Clin Cancer Res. 2017 Apr 1;23(7):1710-1721. doi: 10.1158/1078-0432.CCR-15-2851. Epub 2016 Oct 4. Clin Cancer Res. 2017. PMID: 27702820 Free PMC article.
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. Diamond JR, et al. Among authors: sams s. Breast Cancer Res. 2018 Aug 2;20(1):82. doi: 10.1186/s13058-018-1014-y. Breast Cancer Res. 2018. PMID: 30071865 Free PMC article. Clinical Trial.
Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer.
Williams MM, Spoelstra NS, Arnesen S, O'Neill KI, Christenson JL, Reese J, Torkko KC, Goodspeed A, Rosas E, Hanamura T, Sams SB, Li Z, Oesterreich S, Riggins RB, Jacobsen BM, Elias A, Gertz J, Richer JK. Williams MM, et al. Among authors: sams sb. Cancer Res. 2021 Feb 1;81(3):732-746. doi: 10.1158/0008-5472.CAN-20-1200. Epub 2020 Nov 12. Cancer Res. 2021. PMID: 33184106 Free PMC article.
Don't Be Fooled by DCIS.
Brown RJ, Sams S, Wolverton DE, Chong T, Borges VF, Rabinovitch RA, Murphy CD. Brown RJ, et al. Among authors: sams s. Oncology (Williston Park). 2017 Jul 15;31(7):549-51, 560-1. Oncology (Williston Park). 2017. PMID: 28712099 No abstract available.
76 results